Calcium channel and beta-receptor antagonists and agonists in MG.
Myasthenia Gravis Center, Karolinska Institute, Stockholm, Sweden.
G
G
Matell
S
S
Bjelak
I
I
Jonkers
R
R
Pirskanen
J
J
Van Vliet
C
C
Swerup
D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D000075202:Contraindications; D018592:Cross-Over Studies; D004558:Electric Stimulation; D018737:Hand Strength; D006801:Humans; D007275:Injections, Intravenous; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D009157:Myasthenia Gravis / Q000503:physiopathology*; D011433:Propranolol / Q000008:administration & dosage / Q000494:pharmacology*; D016037:Single-Blind Method; D013726:Terbutaline / Q000008:administration & dosage / Q000494:pharmacology*; D014700:Verapamil / Q000008:administration & dosage / Q000494:pharmacology*
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D011433:Propranolol; D014700:Verapamil; D013726:Terbutaline